Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2021

01-08-2021 | Metastasis | ASO Author Reflections

ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases

Authors: Shin Kobayashi, MD, PhD, Yoshiaki Nakamura, MD, PhD, Shinichiro Takahashi, MD, PhD, Hiroya Taniguchi, MD, PhD, Takayuki Yoshino, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2021

Login to get access

Excerpt

Numerous studies have proposed risk-scoring systems after hepatectomy for resectable colorectal liver metastases (CRLM) to guide perioperative treatment. Recent developments of precision oncology have demonstrated that molecular markers such as RAS, BRAF V600E, PIK3CA, SMAD4, and TP53 predict poor prognosis.1,2 However, since all of them were analyzed by tissue-based polymerase chain reaction or next-generation sequencing, it was not possible to timely incorporate the information regarding genomic alterations into guiding perioperative treatment at time of diagnosis for CRLM. …
Literature
1.
Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. Oct 1 2019;25(19):5843–5851.CrossRef
2.
Kobayashi S, Takahashi S, Takahashi N, et al. Survival outcomes of resected BRAF V600E mutant colorectal liver metastases: a multicenter retrospective cohort study in Japan. Ann Surg Oncol. Jul 13 2020.
3.
Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. Oct 5 2020.
4.
5.
Metadata
Title
ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases
Authors
Shin Kobayashi, MD, PhD
Yoshiaki Nakamura, MD, PhD
Shinichiro Takahashi, MD, PhD
Hiroya Taniguchi, MD, PhD
Takayuki Yoshino, MD, PhD
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09456-9

Other articles of this Issue 8/2021

Annals of Surgical Oncology 8/2021 Go to the issue

Thoracic Oncology

Unlocking Better Survival for Esophageal Cancer Patients: Is Thoracic Duct Resection the Key?

Pancreatic Tumors

Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma

ASO Author Reflections

ASO Author Reflections: Pretherapeutic Naples Prognostic Score in Locally Advanced Esophageal Cancer

ASO Author Reflections

ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?

ASO Author Reflections

ASO Author Reflections: Severe Morbidity After Major Surgery in Patients with MEN1

ASO Author Reflections

ASO Author Reflections: The Frailty of Patient Selection